BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 30110065)

  • 1. Immunhistochemical analysis of Nuclear Factor Kappa Beta expression in etiopathogenesis of ovarian tumors1.
    Yilmaz E; Gul M; Melekoglu R; Koleli I
    Acta Cir Bras; 2018 Jul; 33(7):641-650. PubMed ID: 30110065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Well-differentiated serous neoplasms of the ovary.
    Longacre TA; Kempson RL; Hendrickson MR
    Pathology (Phila); 1993; 1(2):255-306. PubMed ID: 9420921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations.
    Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR
    Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
    Pisharodi LR; Bedrossian CW
    Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
    Tan Y; Sinniah R; Bay BH; Singh G
    J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostaining Study on the Expression of NF-κB, ER, and PR in Ovarian Serous Carcinoma.
    Lin J; Xi C; Liu C; Wang Y; Liu Y; Ren C; Liu C
    Int J Gynecol Pathol; 2017 Jan; 36(1):58-63. PubMed ID: 27171541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
    Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and clinical relevance of ARHI, STAT3 and E2F1 in ovarian serous carcinoma].
    Zhang J; Li YH; Cui AR; Wang JL; Cheng JX; Wang SJ
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):905-9. PubMed ID: 19173990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squash cytodiagnosis of synchronous papillary serous carcinoma of ovary and endometrium with demonstration of serous tubal intraepithelial carcinoma as a precursor lesion.
    Kar A; Kar T; Dha I; Panda S
    Indian J Pathol Microbiol; 2017; 60(1):125-127. PubMed ID: 28195111
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Romanini C; Biagini G
    Anticancer Res; 1996; 16(4A):2123-7. PubMed ID: 8712754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and significance of GLUT-1 and DNA-PKcs in serous ovarian tumors].
    Cai Y; Shao SL; Wang QH; Yan LJ; Wang XY; Wang LX
    Ai Zheng; 2007 Nov; 26(11):1188-93. PubMed ID: 17991316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of THY1 gene in epithelial ovarian cancer].
    Zeng LQ; Peng ZL; Duan ZL
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):118-20. PubMed ID: 19538887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance].
    Shao SL; Cai Y; Wang QH; Yan LJ; Zhao XY; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):697-700. PubMed ID: 18246802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
    Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
    Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serous papillary cystadenocarcinoma arising from autografted ovary of the abdominal wall.
    Gong W; Cheng H; Yan Q; Huang G; Luo P; Wang Z
    Int J Surg Pathol; 2010 Oct; 18(5):398-400. PubMed ID: 19147508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.